Boston, MA 09/11/2014 (wallstreetpr) – Medical device manufacturer, Boston Scientific Corporation (NYSE:BSX) would present data at the 26th Transcatheter Cardiovascular Therapeutics or TCT meeting to reinforce its commitment towards the development of innovative treatment in interventional cardiology.
Results To Be Shared
Boston Scientific Corporation (NYSE:BSX) disclosed that it would share the results from over a dozen clinical trials during the annual meeting to be held from September 13 – 17 in Washington and conducted by the Cardiovascular Research Foundation, a statement from the company said.
Boston Scientific said that it was fully committed to exploring the ways and means to find how its technologies could provide value-driven solutions for patients affected by cardiovascular disease. It plans to share data in the meeting to further carry on the body of proof illustrating the clinical value of its solutions that would help interventional cardiologists to face the changing requirements of their patients.
The medical device maker said that the most common nature of heart disease, Coronary artery disease, is not only rampant but also expensive. It cost about $108 billion in the U.S. for medications, services and lost productivity since about 380,000 American dies every year due to coronary artery disease. Therefore, there was a continuing requirement for new technologies and therapies to face the growing worldwide problem.
Key Data Presentations
Boston Scientific Corporation (NYSE:BSX) said that it would present data during oral sessions, as well as, posters during the meeting. It plans to poster present its clinical and preclinical studies involving coronary artery multiple stent platforms. The four-year outcome of its Platinum Small Vessel and Long Lesion study and two-year outcome of its Taxus Element Post-Approval Surveillance Trial would be shared during the meeting.
Similarly, other outcomes on Aortic Valves from the REPRISE clinical study would also be shared in the meeting. Boston Scientific Corporation (NYSE:BSX) has one-year and two-year outcomes on REPRISE. The company has also lined up its speakers like Professor Ian Meredith, Vivek Reddy, David Holmes Jr., Mathew Price, George Hanzel and David Kandzari to present the outcome of different studies.
